small nucleolar RNA, H/ACA box 65Genealiases: RNU65 · U65
Q-omics provides the consensus-scored SNORA65 profile across patient tissues and cancer cell-line models. SNORA65 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNORA65 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SNORA65 RNA expression shows 18,220 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where SNORA65 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA65 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA65 survival associations across molecular data types. SNORA65 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA65 RNA expression–survival associations across cancer types. High SNORA65 expression shows unfavorable associations in ACC, KIRC, LAML, LGG and PRAD, but favorable associations in MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SNORA65 RNA expression.
This table summarizes SNORA65 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA65. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA65 shows lower tumor expression in THCA and higher tumor expression in HNSC, READ, STAD, COAD and LUSC. The HNSC box plot shows higher SNORA65 RNA expression in tumor versus normal tissue (log2 FC = +0.561, t-test p < 0.001).
This table shows molecular features associated with SNORA65 in patient tissues and cancer cell lines. In patient samples, SNORA65 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
